NCT04902040 2026-03-18
Plinabulin in Combination With Radiation/Immunotherapy in Patients With Select Advanced Cancers After Progression on PD-1 or PD-L1 Targeted Antibodies
M.D. Anderson Cancer Center
Phase 1/2 Terminated
Clinical Trials
143 trialsNCT06504381 2026-03-11
DB107-RRV, DB107-FC, and Radiation Therapy With or Without Temozolomide (TMZ) for High Grade Glioma
University of California, San Francisco
Phase 1/2 Recruiting
NCT04454528 2026-03-10
BreastVAX
Abramson Cancer Center at Penn Medicine
Phase 1/2 Active not recruiting
NCT06434350 2026-03-02
Enfortumab Vedotin With Radiation for Locally Advanced Bladder Cancer (CONSOLIDATE)
M.D. Anderson Cancer Center
Phase 1/2 Recruiting
NCT07217990 2026-02-17
NoCUT-BC
Ohio State University Comprehensive Cancer Center
Phase 1/2 Not yet recruiting
NCT03529448 2026-02-12
GEINOCANN
Grupo Español de Investigación en Neurooncología
Phase 1/2 Completed
NCT01517451 2026-02-11
Radiation and Androgen Ablation for Prostate Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 1/2 Completed
NCT05039632 2026-02-06
Phase I/II Randomized Study of NBTXR3 Activated by Abscopal or RadScopal Radiation in Combination With Immunotherapy (Anti-PD-1/L-1) for Patients With Advanced Solid Malignancies
M.D. Anderson Cancer Center
Phase 1/2 Recruiting
NCT03474497 2026-01-29
UCDCC#272: IL-2, Radiotherapy, and Pembrolizumab in Patients Refractory to Checkpoint Blockade
University of California, Davis
Phase 1/2 Active not recruiting
NCT03543189 2026-01-29
Combination of Nivolumab Immunotherapy With Radiation Therapy and Androgen Deprivation Therapy
H. Lee Moffitt Cancer Center and Research Institute
Phase 1/2 Active not recruiting
NCT04599062 2026-01-29
TVEC and Preop Radiation for Sarcoma (8 ml Dose)
University of Iowa
Phase 1/2 Active not recruiting
NCT07312422 2026-01-26
LDRT Combined With Pucotenlimab and Standard Therapy for Advanced Pancreatic Cancer: A Single-Arm Study
Zhejiang Provincial People's Hospital
Phase 1/2 Recruiting
NCT00508443 2026-01-15
Evaluation of a Novel CT-On-Rails or Trilogy Stereotactic Spine Radiotherapy System (SSRS)
M.D. Anderson Cancer Center
Phase 1/2 Active not recruiting
NCT02481635 2025-12-08
A Study of Gemcitabine/Nab-paclitaxel and Radiation Therapy Followed by Surgery in Patients With Advanced Pancreatic Cancer
University Health Network, Toronto
Phase 1/2 Active not recruiting
NCT03687957 2025-11-25
rhIL-7-hyFc on Increasing Lymphocyte Counts in Patients With Newly Diagnosed Non-severe Lymphopenic Gliomas Following Radiation and Temozolomide
Washington University School of Medicine
Phase 1/2 Active not recruiting
NCT03217747 2025-10-23
Avelumab, Utomilumab, Anti-OX40 Antibody PF-04518600, and Radiation Therapy in Treating Patients With Advanced Malignancies
M.D. Anderson Cancer Center
Phase 1/2 Active not recruiting
NCT02444741 2025-10-09
Pembrolizumab and Stereotactic Body Radiation Therapy or Non-Stereotactic Wide-Field Radiation Therapy in Treating Patients With Non-small Cell Lung Cancer
M.D. Anderson Cancer Center
Phase 1/2 Active not recruiting
NCT03174197 2025-09-24
Atezolizumab in Combination With Temozolomide and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma
M.D. Anderson Cancer Center
Phase 1/2 Completed
NCT07177950 2025-09-17
A Two-cohort Study of SHR-A1811 in the Treatment of HER2-positive Breast Cancer With Brain Metastases
Peking University Cancer Hospital & Institute
Phase 1/2 Not yet recruiting
NCT05893654 2025-09-15
MELCOM
Hospital das Clínicas de Ribeirão Preto
Phase 1/2 Enrolling by invitation
NCT03148327 2025-07-15
Astra Zeneca (Immuno Stereotactic Ablative Body Radiotherapy) ISABR Study: Randomized Phase I/II Study of Stereotactic Body Radiotherapy
Jonsson Comprehensive Cancer Center
Phase 1/2 Active not recruiting
NCT02730546 2025-06-22
Pembrolizumab, Combination Chemotherapy, and Radiation Therapy Before Surgery in Treating Adult Patients With Locally Advanced Gastroesophageal Junction or Gastric Cardia Cancer That Can Be Removed by Surgery
Mayo Clinic
Phase 1/2 Completed
NCT04019262 2025-06-18
Short Course Chemo-Radiation Therapy for Patients With Newly Diagnosed Glioblastoma
University of Pittsburgh
Phase 1/2 Active not recruiting
NCT01350258 2025-05-31
Bone Marrow Transplant Using a Reduced Intensity Regimen That is Given in Two Steps
Thomas Jefferson University
Phase 1/2 Terminated
NCT04789486 2025-05-23
Nano-SMART: Nanoparticles With MR Guided SBRT in Centrally Located Lung Tumors and Pancreatic Cancer
Dana-Farber Cancer Institute
Phase 1/2 Recruiting
NCT00429143 2025-05-04
A Two-Step Approach to Bone Marrow Transplant Using Cells From A Partially-Matched Relative
Thomas Jefferson University
Phase 1/2 Completed
NCT03523351 2025-04-20
Study of Palliative Radiation Therapy vs. no Palliative Radiation Therapy for Patients With High Risk Bone Metastases That Are Not Causing Significant Pain
Memorial Sloan Kettering Cancer Center
Phase 1/2 Completed
NCT03958383 2025-04-18
IT-hu14.18-IL2 With Radiation, Nivolumab and Ipilimumab for Melanoma
University of Wisconsin, Madison
Phase 1/2 Active not recruiting
NCT05784012 2025-03-13
RADIAN
Grupo Español de Tratamiento de Tumores de Cabeza y Cuello
Phase 1/2 Recruiting
NCT04261855 2025-02-14
GoTHAM
Melanoma and Skin Cancer Trials Limited
Phase 1/2 Recruiting
NCT04881032 2025-02-13
NANO-GBM
Centre Jean Perrin
Phase 1/2 Active not recruiting
NCT03043599 2024-12-20
Ipilimumab + Nivolumab w/Thoracic Radiotherapy for Extensive-Stage Small Cell Lung Cancer
H. Lee Moffitt Cancer Center and Research Institute
Phase 1/2 Completed
NCT04278287 2024-12-13
Chemoradiotherapy in Unresectable Esophageal Cancer
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 1/2 Recruiting
NCT04267146 2024-12-02
NIVOGLIO
Gustave Roussy, Cancer Campus, Grand Paris
Phase 1/2 Completed
NCT02891161 2024-11-27
DUART
Big Ten Cancer Research Consortium
Phase 1/2 Terminated
NCT05501665 2024-10-17
Split Course Adaptive Radiation Therapy With Pembrolizumab With/Without Chemotherapy for Treating Stage IV Lung Cancer
Vanderbilt-Ingram Cancer Center
Phase 1/2 Recruiting
NCT02927964 2024-10-16
TLR9 Agonist SD-101, Ibrutinib, and Radiation Therapy in Treating Patients With Relapsed or Refractory Grade 1-3A Follicular Lymphoma
Stanford University
Phase 1/2 Completed
NCT03453164 2024-09-19
Checkpoint Inhibitor and Radiotherapy for Recurrent Gastric Cancer (CIRCUIT)
Fukushima Medical University
Phase 1/2 Completed
NCT03267888 2024-09-04
Pembrolizumab and Radiation Therapy in Patients With Relapsed or Refractory Multiple Myeloma
Emory University
Phase 1/2 Completed
NCT00321698 2024-08-29
Radiation Therapy and Docetaxel in Treating Patients Who Are Undergoing Surgery for Localized Prostate Cancer
OHSU Knight Cancer Institute
Phase 1/2 Terminated
NCT03338959 2024-07-23
Pembrolizumab and Radiation Therapy in Treating Patients With Intermediate or High-Grade Soft Tissue Sarcoma
Fred Hutchinson Cancer Center
Phase 1/2 Completed
NCT06477523 2024-06-27
Phase 1b/2 Study of LDRT in Combination With AK104 Plus Chemotherapy as First-line Treatment for ES-SCLC
Sichuan University
Phase 1/2 Recruiting
NCT04625907 2024-05-23
FaR-RMS
University of Birmingham
Phase 1/2 Recruiting
NCT06217757 2024-05-13
Safety and Tolerability of LDRT+Sugemalimab+Chemotherapy+Olaparib for First-Line Treatment of SLFN-11 Positive ES-SCLC
Sichuan University
Phase 1/2 Recruiting
NCT05664464 2024-05-10
GLUGLIO
University of Zurich
Phase 1/2 Recruiting
NCT01088347 2024-04-19
Mapatumumab, Cisplatin and Radiotherapy for Advanced Cervical Cancer
University Medical Center Groningen
Phase 1/2 Completed
NCT02735239 2024-03-22
Study of Anti-PD-L1 in Combination With Chemo(Radio)Therapy for Oesophageal Cancer
Ludwig Institute for Cancer Research
Phase 1/2 Completed
NCT06173986 2023-12-18
Immunotherapy in Combination With Chemoradiotherapy in Unresectable Locally Advanced Esophageal Cancer
Shanghai Chest Hospital
Phase 1/2 Recruiting
NCT02275286 2023-05-31
TRASTS
Grupo Espanol de Investigacion en Sarcomas
Phase 1/2 Recruiting
NCT03168464 2023-04-24
Radiation and Immune Checkpoints Blockade in Metastatic NSCLC (BMS # CA209-632)
Weill Medical College of Cornell University
Phase 1/2 Terminated